Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique tumor biology. OCCC is frequently linked to endometriosis and characterized by mutations in ARID1A and PIK3CA, hyperactivation of the PI3K/Akt/mTOR pathway, and overexpression of VEGF, HIF-1α, and IL-6. These features drive tumor proliferation, angiogenesis, immune evasion, and resistance to platinum-based chemotherapy. The tumor microenvironment of OCCC is highly immunosuppressive, with infiltration of regulatory T cells, tumor-associated macrophages, and upregulation of immune checkpoint molecules, such as PD-1, PD-L1, and LAG-3. These characteristics suggest that the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion and could be an attractive target for therapeutic intervention. Despite the typical composition of the immunosuppressive tumor microenvironment in ovarian cancer, until now overall the results of trials testing immune checkpoint inhibitors so far have been disappointing. It is interesting to note instead that several subgroup analyses reported exceptional OCCC sensitivity to ICIs. Indeed, current and preliminary trials exploring ICIs, anti-angiogenic agents, and combinatorial therapies in OCCC show promising outcomes. Strategies targeting multiple pathways, including VEGF, IL-6, HIF-1α, and HDAC6, alongside ICIs, are under investigation to overcome resistance mechanisms. Additionally, IL-10 inhibition or ferroptosis pathway activation offers novel therapeutic potential. Personalized, biomarker-driven approaches, targeting ARID1A and PIK3CA mutations or combining immune and anti-angiogenic agents, are gaining traction in OCCC management. This review highlights OCCC molecular underpinnings and therapeutic challenges, emphasizing the need for innovative, multi-targeted strategies. Advances in understanding genetic-immunological interplay in OCCC may enable more effective and durable treatments and improved patient outcomes.
ovarian clear cell carcinomaARID1A mutationstumor microenvironmentimmune checkpoint inhibitorscombination immunotherapyThe author(s) declare financial support was received for the research and/or publication of this article. The study was partially supported by Ministry of Health Ricerca Corrente L4/81_25 to SP.section-at-acceptanceCancer Immunity and ImmunotherapyIntroduction
Epithelial ovarian carcinoma (EOC) is the deadliest gynecological malignancy and among the leading contributors to cancer-related mortality in women worldwide (1). Up to 90% of ovarian neoplasms are classified as EOC, further divided into the following subtypes based on histopathology: high-grade serous carcinomas, the most prevalent, comprising about 70% of cases; low-grade serous carcinomas, accounting for less than 5%; endometrioid carcinomas (EC), representing 10%; clear cell carcinomas (CCC), also accounting for 10%; and mucinous carcinomas, comprising 3% (2). Ovarian clear cell carcinoma (OCCC) is thought to arise from the malignant transformation of ectopic endometrial tissue located on the ovary. This is supported by the presence of endometriosis in 50–70% of OCCC cases (3), linked to a 2.3-fold increased risk of OCCC development (4–6). As a result, OCCC, along with EC, is classified as an endometriosis-associated ovarian cancer (7–10). OCCC represents a distinct pathological subtype, typically presenting as a large, unilateral pelvic mass that, on histopathological examination, displays a combination of papillary, tubulocystic, and solid growth patterns, along with clear and eosinophilic cells and stromal hyalinization (11). Notably, the presence of intracellular glycogen deposits is a highly distinctive diagnostic feature (12). This subtype exhibits poor responsiveness to platinum-based chemotherapy and is associated with worse outcomes than other EOC subtypes (10, 13). Furthermore, cancer-associated thromboembolism, a vascular thromboembolic complication, occurs more frequently in OCCC than in other histologic EOC subtypes, contributing to an unfavorable prognosis (14–17). When diagnosed at an advanced stage, OCCC is associated with shorter progression-free survival (PFS) and overall survival (OS) and poor chemotherapy response (18). Among patients diagnosed at FIGO stages I–II, OS rates are 80–89%, and PFS ranges from 56% to 88%. In contrast, for FIGO stages III–IV, OS drops to 52%, and PFS declines to 25% (19–22). Interestingly, OCCC is characterized by a typical tumor microenvironment (TME) with a strong immunosuppressive milieu. These characteristics suggest that the PD-1/PD-L1 axis is a key mechanism in tumor immune evasion and represents a potentially valuable target for therapeutic intervention. Although clinical trials evaluating immune checkpoint inhibitors (ICIs) in advanced ovarian cancer have so far produced mostly disappointing results, several subgroup analyses have identified a marked sensitivity of the clear cell ovarian carcinoma (OCCC) histotype to ICIs.
This review further clarifies the unique molecular signature and TME features of OCCC, focusing primarily on the promising role played by the use of immunotherapy.
Methods
Papers to be considered were identified by conducting PubMed searches, using different combinations of pertinent keywords “ovarian clear cell carcinoma,” “OCCC,” “immune checkpoint inhibitors,” “PD-1,” “PD-L1,” “LAG-3,” “ARID1A,” “PIK3CA”, “VEGF,” “tumor microenvironment,” “immune evasion,” “immunosuppression,” “HIF-1α,” “IL-6,” “angiogenesis,” “ferroptosis,” “HDAC6,” “clinical trials,” and “immunotherapy”. Boolean operators (AND, OR) were used to refine the search. Clinical trial data were retrieved from ClinicalTrials.gov using the keyword “ovarian clear cell carcinoma” and filtered for interventional studies involving immunotherapeutic agents or combination therapies. Articles were selected based on their relevance to the pathogenesis, immune modulation, and emerging therapeutic approaches in OCCC.
ResultsOCCC molecular signature
The most frequent genetic alterations observed in OCCC include mutations in the ARID1A, KRAS, PTEN, and PIK3CA genes (23). Additional oncogenic changes affecting the mitogen-activated protein kinase (MAPK) pathway have been reported, such as mutations in PPP2R1A, mutations and amplifications of ERBB2, and amplification of the MET proto-oncogene, which encodes the hepatocyte growth factor receptor (HGFR) (24). Recently, mutations in MUC4, MAGEE1, and ARID3A have been identified at notable frequencies, with MAGEE1 mutations correlating with poorer prognosis (25). Familial inheritance is rare in OCCC, which typically expresses wild-type p53 and exhibits a very low frequency of BRCA1 and BRCA2 mutations (26), while TERT promoter mutations occur more commonly (27).
OCCC is characterized by high expression levels of napsin A, hypoxia-inducible factor 1-alpha (HIF-1α) (28), glypican-3 (29), hepatocyte nuclear factor 1-beta (HNF-1β) (30), interleukin 6 (IL-6) (31), and MET (32), whereas estrogen receptor expression is generally absent (33, 34). Although cancer antigen 125 (CA125) levels are usually low in OCCC, elevated CA125 correlates with worse prognosis (35).
ARID1A, encoding the chromatin remodeler BAF250, is involved in transcriptional regulation, DNA synthesis, and cellular proliferation and differentiation. Mutations in ARID1A occur in approximately 50% of OCCC cases and represent an early event in tumorigenesis (36). ARID1A loss impairs interferon signaling, facilitating immune evasion (37), and is associated with increased expression of HDAC6, which promotes tumor cell invasion, migration, and poorer overall survival (38–40). The co-occurrence of ARID1A and PIK3CA mutations leads to hyperactivation of the phosphoinositide 3-kinase (PI3K) pathway via p110α, stimulating the PI3K/Akt/mammalian target of rapamycin (mTOR) cascade and enhancing cellular proliferation (33, 41–44).
Recent evidence implicates the PI3K/Akt/mTOR and extracellular signal-regulated kinase 1/2 (ERK1/2) pathways in OCCC chemoresistance. These pathways regulate progranulin (PGRN) overexpression (45) and induce HIF-1α expression, which promotes metabolic adaptations including increased glycogen accumulation in PIK3CA-mutated OCCC cells and contributes to chemoresistance (46). Furthermore, Akt/mTOR signaling upregulates vascular endothelial growth factor (VEGF), driving tumor angiogenesis critical for growth, invasion, and metastasis (47). The PI3K/Akt pathway also mediates resistance to ferroptosis, an iron-dependent oxidative stress-induced form of cell death, which is regulated by the Hippo signaling pathway (48). Notably, reduced Hippo pathway activity, particularly low nuclear expression of yes-associated protein 1 (YAP1) correlates with poor prognosis and resistance to ferroptosis inducer erastin. Suppression of zinc finger DHHC-type palmitoyltransferase 7 (ZDHHC7) activates YAP1, sensitizing OCCC cells to ferroptosis, suggesting that targeting ZDHHC7 to enhance YAP1-mediated ferroptosis represents a promising therapeutic approach (49).
Decreased PTEN expression or inactivation, known to promote gastric cancer via Hippo and PI3K/Akt pathway activation (50), may similarly contribute to OCCC pathogenesis. In OCCC, low PTEN levels lead to hyperactivation of the PI3K/Akt pathway and, when combined with ARID1A mutations, promote programmed death-ligand 1 (PD-L1) expression (51).
Combined ARID1A and PIK3CA mutations also elevate IL-6 expression, a known ARID1A-regulated gene (52). PIK3CA mutations drive sustained IL-6 production through PI3K/Akt hyperactivation in the context of ARID1A loss (36). IL-6 maintains JAK/STAT3 signaling, amplifying its own expression and promoting resistance to oxidative stress, tumor invasion, and chemoresistance (53–56). IL-6 additionally induces nuclear translocation and transcriptional activation of HIF-1α via STAT3, enhancing cisplatin resistance in ovarian cancer cells (57). HIF-1α, highly expressed in OCCC, contributes to glycogen accumulation, metabolic adaptation, and activation of IL-6 signaling (28, 46, 58). Through STAT3 activation, IL-6 induces VEGF expression, promoting angiogenesis and vascular permeability. Correspondingly, ARID1A mutations correlate with elevated VEGF levels, aggressive tumor phenotype, poor survival, and cisplatin resistance (59). VEGF also plays a role in tumor progression and exerts immunosuppressive effects in OCCC (60).
HNF-1β expression is characteristic of both endometriosis and OCCC, suggesting early differentiation of endometriosis into clear cell lineage. RNA interference studies show that HNF-1β is essential for OCCC cell survival, with its knockdown inducing apoptosis. HNF-1β promotes glycogen synthesis and aerobic glycolysis, contributing to the metabolic reprogramming that supports chemoresistance (61). Despite its importance, no targeted therapies against HNF-1β have yet been developed, highlighting the need for further investigation (62).
The HGFR signaling pathway is critical for cell growth, survival, and motility through activation of RAS-MAPK, PI3K/Akt/mTOR, and JAK/STAT3 pathways (63, 64). HGFR also functionally interacts with HIF-1α, regulating VEGF expression (65).
OCCC frequently exhibits mismatch repair deficiency (MMRd), resulting in accumulation of genetic abnormalities and microsatellite instability (MSI) (66, 67). MSI arises from mutations or methylation in mismatch repair genes such as MLH1, MSH2, and MSH6 (68). ARID1A mutations contribute to MMRd and MSI by disrupting protein interactions with MSH2 and promoting somatic MLH1 methylation (52, 69, 70). High MSI (MSI-H) occurs in 2–20% of ovarian cancers, predominantly in endometrioid carcinoma (EC) and OCCC (71). Diffuse intratumoral stromal inflammation has been reported as a histologic marker of MMRd in OCCC (72). OCCC tumors with MSI-H are highly immunogenic, exhibiting increased tumor-infiltrating lymphocytes (TILs) and elevated PD-L1 expression, which may predict enhanced responsiveness to immune checkpoint blockade (ICB) therapies (71, 73, 74).
In summary, the molecular landscape of OCCC converges on five major oncogenic pathways: PI3K/Akt/mTOR, HIF-1α/VEGF, HNF-1β, IL-6/STAT3, and HGFR. These interconnected signaling networks orchestrate tumor growth, angiogenesis, immune evasion, metabolic adaptation, and drug resistance, providing a strong rationale for the development of multi-targeted therapeutic strategies (Figure 1) (11, 75–77).
Gene mutations in OCCC and their association with the activation of pro-tumoral signaling pathways. PI3KCA/PTEN mutations induce high levels of PI3K/Akt/mTOR activation, which increases the expression and signaling of IL-6 and the expression of VEGF. VEGF, in turn, promotes angiogenesis and enhances the activity of Tregs and MDSCs, contributing to immunosuppression. IL-6, through its interaction with its receptor, activates STAT3, which enhances the nuclear translocation and transcriptional activity of HIF-1, resulting in chemoresistance and proliferation. Conversely, HIF-1 enhances the activation of STAT3. ARID1A mutations lead to increased levels of HDAC6. HDAC6 increases IL-10 expression, which, in turn, promotes the polarization of macrophages toward an M2 pro-tumoral phenotype, leading to IL-6 secretion and supporting immunosuppression. Concomitant mutations of ARID1A and PTEN promote the expression of immune checkpoints such as LAG-3 and PD-L1, contributing to T-cell anergy and the differentiation of Tregs.
Diagram illustrating the signaling pathways involved in ovarian clear cell carcinoma (OCCC) progression. It shows how PI3KCA/PTEN and ARID1A mutations lead to increased IL-6 signaling and angiogenesis, contributing to immune escape, cell proliferation, invasion, and chemoresistance through pathways like IL-6R/JAK/STAT3. M0 macrophages polarize to M2, further aiding immune evasion. Mutations also affect PD-L1 and LAG-3 expression, T-cell anergy, and Tregs differentiation, exacerbating the tumor environment. Orange boxes highlight key processes like immune escape and inflammation.The immune tumor microenvironment in OCCCAnti-tumor immunity and the establishment of an immunosuppressive and pro-tumor TME
The TME constitutes a complex and dynamic milieu comprising cellular components, including cancer cells, endothelial cells, fibroblasts, granulocytes, lymphocytes, and macrophages, embedded in an altered extracellular matrix (ECM) (78). The ECM not only supports tumor architecture but also orchestrates cell-to-cell and cell-to-matrix signaling, and is enriched in inflammatory mediators, chemokines, and matrix-degrading enzymes, such as metalloproteinases, which drive matrix breakdown, neoplastic invasion, and angiogenic processes (79, 80). The immunomodulatory potential of the TME depends on its cellular composition, influencing both innate and adaptive immune responses (81). Among its immune components, TILs are critical for identifying and eradicating malignant cells via both innate defenses and antigen-specific mechanisms (82). Antigen-presenting cells (APCs) initiate adaptive responses by activating CD4+ T helper cells (Th1, Th2, Th17), regulatory T cells (Tregs), and cytotoxic T lymphocytes (CTLs) (75, 83, 84). Innate immunity relies on natural killer (NK) cells and macrophages. NK cells eliminate tumors with reduced major histocompatibility complex (MHC) expression (85), while M1-polarized macrophages produce pro-inflammatory cytokines (e.g., IL-6, IL-12, IFN-γ) and facilitate antigen presentation (86). However, the TME often impairs immune responses, recruiting Tregs, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), which promote immunosuppression and tumor progression (87–89). Immune evasion is supported by the expression of immune checkpoints, including cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and lymphocyte activation gene 3 (LAG-3), which inhibit T-cell activation (90–92). Hypoxia, a hallmark of the TME due to abnormal vasculature and high tumor cell proliferation, exacerbates immunosuppression by recruiting MDSCs, TAMs, and Tregs (93). HIFs, particularly HIF-1α, promote tumor cell survival, inflammation, and immune escape (94). Tumor-associated neutrophils and cancer-associated fibroblasts (CAFs) further reshape the TME, enhancing tumor growth, invasion, angiogenesis, and drug resistance (95, 96). In summary, the TME fosters tumor progression and immune evasion by altering immune cell phenotypes, creating hypoxic conditions, and facilitating intercellular communication, ultimately leading to metastatic potential and treatment resistance (97, 98).
Characteristics of the TME in OCCC
As for many types of cancer, the TME plays a crucial role in driving the aggressiveness and immune escape of ovarian cancer (99). Specifically, the TME in OCCC is characterized by a hypoxic environment that supports glycogen synthesis and accumulation (46). Chemoresistant subpopulations of OCCC cells exhibiting elevated HIF activity have been identified in areas enriched with CAFs that display a myofibroblastic phenotype (myCAFs). Indeed, myCAFs enhance OCCC chemoresistance and induce HIF-1α activity, mediated by platelet-derived growth factor (PDGF) signaling through PDGF receptors expressed by CAFs (100).
The OCCC TME displays a high-iron content feature, thought to derive from CD10-negative, endometriosis-derived mesenchymal stem cells (enMSCs) that support tumor growth by donating iron. These enMSCs overexpress iron-export proteins, increasing labile intracellular iron levels, which promote OCCC cell proliferation while shielding them from iron chelation therapies. However, this enhanced iron transfer simultaneously renders OCCC cells vulnerable to ferroptosis, identifying a potential therapeutic target for treatment (101).
Regarding immune escape, several studies have identified aberrant expression of various immune checkpoint genes in OCCC, including CTLA-4, PD-1, PD-L1, LAG-3, and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), positioning these as potential targets for ICB therapies. Collectively, these findings suggest that OCCC may be particularly responsive to ICB strategies (102). PD-L1 have been shown to be expressed in ovarian tumors and to represent negative prognostic markers. Moreover, PD-L1 promote immune evasion by inducing T-cell anergy or apoptosis, favoring tumor immune escape (103). In OCCC, PD-L1 expression is driven by ARID1A mutations (104, 105) and the hyperactivation of the PI3K/Akt pathway (51). The interaction of PD-L1 with PD-1 on T cells triggers inhibitory signals that suppress activated T lymphocytes, promote T-cell anergy and apoptosis, and ultimately lead to the activation and expansion of Tregs (106). VEGF expression plays an important role in the tumor progression of OCCC and, in addition to promoting angiogenesis, acts as an immunosuppressive agent by impairing T-cell function and APC function, and activating Tregs and MDSCs (60). The increased presence of Tregs within the OCCC TME has been associated with tumor progression and resistance across multiple stages of the disease (107). Moreover, frequent alteration of the PI3K/Akt/mTOR pathway observed in OCCC not only upregulates PD-L1 expression but also enhances the expression of LAG-3. This dual activation promotes resistance to cytotoxic T-cell-induced apoptosis, enhances Treg function, and enables evasion from death receptor-mediated signaling (108–111).
The expression of LAG-3 in TILs has been reported in OCCC and is associated with a poor prognosis (112). Furthermore, recent studies showed that the ARID1A6488delG mutation (113) induces M2 polarization of macrophages through IL-10, thus contributing to differentiation into TAMs and immunosuppressive conditions (40).
In summary, the OCCC TME is characterized by a hypoxic, iron-rich, and immunosuppressive profile, featuring the infiltration of Tregs and TAMs (Figure 2) (103, 114, 115).
Characteristics of the OCCC TME. The OCCC TME is highly immunosuppressive and pro-tumorigenic. This is characterized by hypoxia and angiogenesis driven by VEGF and HIF-1α, which promote tumor growth and chemoresistance. Endometriosis-derived mesenchymal stem cells (enMSCs) enrich the microenvironment with iron, sustaining OCCC proliferation but also conferring vulnerability to ferroptosis. Cancer-associated fibroblasts with a myofibroblastic phenotype (myCAFs) contribute to chemoresistance and enhance HIF-1α activity through PDGF signaling. The immune landscape includes regulatory T cells (Tregs) and M2-polarized macrophages, which suppress anti-tumor responses, alongside aberrant expression of immune checkpoints such as PD-1, PD-L1, and LAG-3 that promote T-cell anergy. Together, these features foster immune escape, therapeutic resistance, and disease progression.
Diagram illustrating interactions between ovarian clear cancer cells and various cells in the tumor microenvironment. Key elements include Treg cells with PD-1 and LAG3, M2 macrophages, endothelial cells, enMSCs, and myCAFs. Pathways involve PDGF promoting chemoresistance, VEGF leading to angiogenesis, and ferritin's role in cancer cell proliferation and vulnerability to ferroptosis. Labels indicate processes such as hypoxic environment and angiogenesis, highlighting molecular interactions like PD-L1 on cancer cells with PD-1 on Treg cells.Immune therapeutic strategies against OCCC
Despite the strong rationale for response to immunotherapy in OCCC, its clinical efficacy in EOC remains limited. Nevertheless, several ongoing clinical trials are exploring the use of immune checkpoint inhibitors (ICIs) in patients with advanced OCCC. Additionally, anti-angiogenic therapies have demonstrated potential in enhancing the efficacy of immunotherapy by modifying the TME and directly influencing immune effector cells (116).
In this regard, in newly diagnosed stage III or IV ovarian carcinoma, the IMagyn050/GOG 3015/ENGOT-OV39 phase III trial (NCT03038100) evaluated the addition of the PD-L1 inhibitor atezolizumab to standard platinum-based chemotherapy and bevacizumab. While no significant improvements were seen in PFS or OS (co-primary endpoints), post hoc subgroup analyses reported a numerical increase in PFS with the addition of atezolizumab in non-high grade serous histology, which included OCCC (117). The phase III study, NINJA (JapicCTI-153004), compared nivolumab (PD-1 inhibitor) with chemotherapy (gemcitabine or pegylated liposomal doxorubicin) in patients with platinum-resistant ovarian cancer. Although nivolumab was better tolerated and associated with a longer duration of response, it did not improve OS and showed inferior PFS compared with chemotherapy (118).
A phase II trial evaluated pembrolizumab in two cohorts of patients with recurrent ovarian cancer, stratified by treatment history and platinum-free intervals (NCT02674061). The overall response rate (ORR) was low—7.4% in cohort A (1–3 prior therapies) and 9.9% in cohort B (4–6 prior therapies)—with modest disease control rates (approximately 37%) in both groups. PD-L1 expression was associated with slightly higher responses (ORR 10%). PFS was 2.1 months, and OS was 17.6 months in cohort B (not reached in cohort A) (119).
The combination of nivolumab and ipilimumab (CTLA-4 inhibitor) in EOC yielded a higher ORR and slightly prolonged PFS than nivolumab alone, with manageable toxicity (NCT02498600). Notably, patients with OCCC demonstrated a fivefold higher ORR than other histologic subtypes, although the sample size was small (12% OCCC) (120).
Further supporting this trend, the results of the BrUOG 354 trial were absolutely promising and surprising. The BrUOG 354 trial (NCT03355976), a randomized two-stage, phase II study, evaluated nivolumab monotherapy versus nivolumab in combination with ipilimumab (nivolumab/ipilimumab) in patients with relapsed extra-renal CCC, including ovarian, endometrial, and cervical primaries. All participants had gynecologic tumors, with 36 (82%) diagnosed with OCCC. Patients had received a median of one prior line of therapy (range 1-7). The ORR was 14.3% (two partial responses) with nivolumab and 33% (four complete and six partial responses) with nivolumab/ipilimumab. Median PFS was 2.2 months (95% CI: 1.2–3.4) with nivolumab and 5.6 months (95% CI: 1.6–29.1) with nivolumab/ipilimumab. Median OS was 17.0 months (95% CI: 2.1–NR) with nivolumab and 24.6 months (95% CI: 5.9–NR) with nivolumab/ipilimumab. Grade 3 treatment-related adverse events occurred in 21% of patients on nivolumab and 47% of those on nivolumab/ipilimumab (including two grade 4 pancreatic enzyme elevations), with no treatment-related deaths reported. These results highlight the meaningful and durable clinical activity of nivolumab/ipilimumab, particularly in OCCC, and support its further evaluation in this historically chemotherapy-resistant population (121).
There are several ongoing clinical trials of anti-angiogenic therapy in combination with ICIs recruiting patients with OCCC. The combination of pembrolizumab (PD-1 inhibitor) with lenvatinib, an oral multikinase inhibitor that targets VEGF receptor, fibroblast growth factor receptor 1–3, PDGF receptor, RET, and KIT, has been evaluated in several gynecologic malignancies and is currently approved by the US Food and Drug Administration (FDA) for use in advanced, microsatellite stable, MMR proficient endometrial carcinoma (122). This combination has been shown to improve PFS and OS in endometrial cancer regardless of histologic subtypes. However, a post-hoc analysis suggests a specific clinical benefit in the clear cell histological subtype (123). In this regard, two phase II clinical trials on the combination of lenvatinib plus pembrolizumab are currently recruiting patients with recurrent or persistent OCCC who have received at least one prior line of platinum-based chemotherapy. The LARA phase II trial (Singapore and South Korea, NCT04699071) evaluates the combination of pembrolizumab and lenvatinib in recurrent clear cell gynecological cancer. The preliminary efficacy reported achieving an objective response in four out of 15 patients in the first 24 weeks (ORR at 24 weeks, 26.7%; 95% CI: 7.8–55.1). The median PFS was 12 weeks (95% CI: 5.4–24.4); PFS at 12 and 24 weeks was achieved in 46.7% (95% CI: 21.2–68.7) and 33.3% (95% CI: 12.2–56.4) of patients, respectively (124).
Similarly, the NCT05296512 trial is recruiting patients with recurrent or persistent OCCC in the USA to undergo an experimental combination of pembrolizumab and lenvatinib (125, 126). Interestingly, McNamara and colleagues reported the case of a patient with recurrent treatment-resistant OCCC with ARID1A/PIK3CA mutations after failing standard and experimental treatments, who had a partial and durable response with pembrolizumab and lenvatinib over 7 months of treatment approved on a compassionate basis (127). Regarding the use of immunotherapy, two recent single-arm, multicenter, phase II trials reported interesting data at the European Society for Medical Oncology (ESMO) 2022 congress. The British PEACOCC (NCT03425565) study enrolled 49 recurrent CCC, of whom 85.4% were OCCC. The study exhibited the promising efficacy of pembrolizumab monotherapy with a 12-week PFS rate of 43.8% (95% CI: 31.5–56.6) (128).
Furthermore, the Chinese INOVA (NCT04735861) study investigated the potential benefit of combining sintilimab (PD-1 inhibitor) and bevacizumab for recurrent or persistent OCCC (129). Preliminary results on 23 patients (of whom 18 were platinum-resistant and 20 with radiological evaluation) reported an ORR of 40% (one complete and seven partial responses; 95% CI: 19.1–63.9) and a disease control rate of 75% (eight partial responses, seven stable diseases; 95% CI: 50.9–91.3%) (130).
Notably, MITO 27 (NCT04375956), a prospective non-randomized phase II study, evaluates the use of pembrolizumab only for patients with a combined positive score >1 in recurrent, platinum-resistant OC, including clear cell histology (131).
The MOCCA trial (NCT03405454) testing durvalumab, an anti-PD-L1 monoclonal antibody, versus standard chemotherapy in patients with recurrent OCCC showed no significant difference in PFS, ORR, or clinical benefit rate. However, correlative translational analyses to elucidate potential predictive biomarkers of response and resistance are ongoing (132).
Finally, BOUQUET (NCT04931342) is a phase II, open-label, non-randomized, multicenter, platform study evaluating biomarker-driven treatments in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal tumors of rare epithelial histology, including OCCC (133). The treatment arm to which eligible patients are assigned will be determined by the biomarker profile of their tumor. Recently, the first interim results have been reported from the cobimetinib arm, a mitogen-activated extracellular signal-regulated kinase 1 (MEK1) inhibitor and from the role of combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) arm. Specifically, as of the clinical cut-off date, five patients with OCCC had received cobimetinib, and three patients with OCCC had received the combination with bevacizumab and atezolizumab. All patients were heavily pretreated. Confirmed objective response rates were 16% with cobimetinib and 14% with atezolizumab plus bevacizumab. This trial continues to evaluate biomarker-driven therapies for rare epithelial ovarian cancer (134).
Recently, a press release from Merck announced that the phase 3 KEYNOTE-B96/ENGOT-ov65 trial (NCT05116189) assessing pembrolizumab plus paclitaxel with or without bevacizumab reached the primary endpoint of PFS among patients with platinum-resistant ovarian cancer across the all-comer and PD-L1-positive populations.
Table 1 summarizes the findings of the clinical trials presented.
Clinical trials with immune checkpoint inhibitors enrolling patients with advanced OCCC.
Clinical trial
Drug
Mechanism of action
Phase
Condition or disease
Drug combinations
Recruitment status
NCT03405454 (MOCCA) (132)
Durvalumab
Anti-PD-L1 mAb
II
OCCC
Durvalumab
Unknown
NCT03355976 (BrUOG 354) (135)
NivolumabIpilimumab
Anti-PD-1 mAbAnti-CTLA-4 mAb
II
Ovarian and extra-renal clear cell carcinomas
Nivolumab ± ipilimumab
Active, not recruiting
NCT04699071 (LARA) (136)
Pembrolizumab
Anti-PD-1 mAb
II
Recurrent gynecological clear cell carcinoma
Pembrolizumab + lenvatinib
Unknown (Singapore)
NCT05296512 (122)
Pembrolizumab
Anti-PD-1 mAb
II
OCCC
Pembrolizumab + lenvatinib
Recruiting (USA)
NCT05026606 (EON) (137)
NivolumabEtigilimab
Anti-PD-1 mAbAnti-TIGIT mAb
II
OCCC
Nivolumab + Etigilimab
Recruiting
NCT05032040 (138)
XmAb20717 (Vudalimab)
Bispecific antibody targeting PD-1 and CTLA-4
II
Refractory clear cell ovarian, endometrial, or peritoneal cancer
NCT, National Clinical Trials identifier; OCCC, ovarian clear cell carcinoma; mAb, monoclonal antibody; PD-L1, programmed death-ligand 1; PD-1, programmed cell death protein 1; CTLA-4, cytotoxic T-lymphocyte antigen 4; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; VEGF, vascular endothelial growth factor; CPS, combined positive score.
Possible new therapeutic strategies and future perspectives in OCCC treatment
Given the complexity of the OCCC TME, therapeutic strategies that combine ICIs with agents targeting key molecules implicated in tumor aggressiveness such as VEGF, HIF-1α, IL-6, IL-10, PI3K, and HDAC6 show considerable promise (Figure 3).
Potential therapeutic strategies targeting the OCCC TME. The diagram illustrates the multifaceted effects of combining targeted therapies counteracting key tumor-promoting pathways (IL-6/IL-6R/STAT3, HIF-1α, VEGF/VEGFR, PD-1/PD-L1, LAG3, and HDAC) on tumor growth, immune modulation, angiogenesis, and chemoresistance. Checkpoint inhibitors (anti-PD-1, anti-PD-L1, and anti-LAG-3) restore T-cell activation and effector function, while anti-VEGF and anti-VEGFR therapies inhibit angiogenesis and tumor vascularization. Inhibition of the IL-6 signaling pathway with anti-IL-6, anti-IL-6R, or anti-STAT3 antibodies, alone or in combination with anti-HIF-1α, leads to reduced angiogenesis, invasion, and chemoresistance. Additional strategies such as anti-HDAC agents might further enhance T-cell activity and reduce immunosuppression macrophage polarization. The combined effects of these therapeutic approaches potentially result in a more immunostimulatory tumor microenvironment and attenuation of OCCC progression.
Diagram illustrating various interactions and pathways related to anti-cancer therapies targeting PD-1, PD-L1, VEGF, HIF-1α, STAT3, IL-6, and HDAC. These interactions focus on restoring T-cell activity, inhibiting angiogenesis, reducing chemoresistance, and preventing invasion. Key components such as endothelial cells, VEGF, and macrophages are shown, with arrows indicating the flow of influence and inhibition lines showing targeted interventions.
Notably, an in vivo study employing animal models demonstrated that combining HDAC6 inhibition via ACY1215 with ICIs constitutes a potential therapeutic approach for ARID1A-mutated OCCC, effectively limiting tumor progression through a cytotoxic T-cell-dependent mechanism (139).
EZN-2208, an inhibitor of HIF-1α, has displayed anti-tumor activity both as monotherapy and in combination with bevacizumab in phase I clinical trials involving refractory solid tumors (140, 141). Additionally, an in vitro study revealed that PX-478, another HIF-1α inhibitor, enhanced T cell-mediated tumor cell killing when combined with ICIs in non-small cell lung cancer models (142). Beyond ICIs, HIF-1α inhibitors may also be combined with anti-angiogenic agents, representing a promising strategy in OCCC. Considering the interplay between HIF-1α and IL-6, dual inhibition targeting IL-6, its receptor, or downstream STAT3 signaling alongside HIF-1α may provide an effective therapeutic avenue.
Co-inhibition of PD-1 and CTLA-4 has demonstrated antitumor efficacy in OCCC patients; however, this approach is often limited by severe immune-related adverse events (120, 143). Given these limitations, a randomized phase III trial in melanoma showed that combined inhibition of PD-1 and LAG-3 resulted in improved clinical outcomes (78), suggesting that targeting PD-1 and LAG-3, rather than PD-1 and CTLA-4, could be a safer and potentially more effective strategy in OCCC. Currently, only a few early-phase clinical studies (phases 1 and 2) have investigated anti-LAG-3 monoclonal antibodies (mAbs) as monotherapy or in combination with other ICIs such as anti-PD-1 and anti-CTLA-4 in advanced solid tumors, including ovarian cancer. Despite strong scientific rationale, no clinical trials specifically evaluating anti-LAG-3 therapy in OCCC have been reported to date.
Moreover, inhibition of IL-6 signaling through the IL-6 receptor alpha (IL-6Rα) inhibitor tocilizumab has been shown to enhance the efficacy of cytotoxic chemotherapy by promoting cytotoxic T lymphocyte (CTL)-mediated antitumor responses, concurrently downregulating PD-L1 expression and potentially augmenting responses to ICIs (144).
IL-10 blockade—achieved using soluble IL-10 receptors (145), peptide-based IL-10 receptor antagonists (146), or oligonucleotide-based inhibitors (147)—may further potentiate antitumor immunity in OCCC by augmenting T-cell responses and reprogramming tumor-associated macrophages (TAMs). These immunomodulatory effects could be synergistically enhanced when combined with IL-6 and VEGF inhibition or ICIs.
Inhibition of the PI3K/Akt/mTOR and ERK1/2 signaling pathways has been shown to reduce progranulin (PGRN) expression in ovarian cancer cells, suggesting a potential strategy to overcome chemoresistance in OCCC. Alpelisib (BYL719), the first oral isoform-selective PI3K inhibitor targeting the p110α isoform of wild-type PI3Kα, has received FDA and EMA approval for metastatic breast cancer treatment (148). Alpelisib has also been employed in advanced gynecologic malignancies harboring PIK3CA mutations, including ovarian cancer. While the most notable clinical benefit has been observed in endometrial cancer patients (149), including a documented case of PIK3CA-mutated endometrial cancer achieving a clinically meaningful response (150), in ovarian cancer cohorts, patients with OCCC demonstrated a disease control rate of 50% (2 stable disease, 1 partial response) (149).
Therefore, it is crucial that translational research focuses on finding valid predictive biomarkers of response to new personalized therapies in addition to the potential expression of PD-L1 and the critical importance of designing clinical trials specifically dedicated to the OCCC histotype.
Conclusion
OCCC represents a challenging subtype of EOC, owing to its distinct molecular features, limited response to conventional therapies, a poor prognosis and highly immunosuppressive TME. Frequent genetic and molecular alterations in OCCC, including ARID1A and PIK3CA mutations, lead to hyperactivation of the PI3K/Akt/mTOR pathway and the overexpression of IL-6, IL-10, HDAC6, VEGF, and HIF-1α, collectively driving its aggressive behavior, chemoresistance, and immune evasion.
The immunosuppressive TME of OCCC, characterized by a high infiltration of Tregs, TAMs, and elevated levels of immune checkpoint molecules such as PD-L1 and LAG-3, could be an attractive target for the immune therapeutic intervention.
These features underline the complexity of managing OCCC and highlight the urgent need for innovative therapeutic approaches, including immunotherapy.
Despite increasing understanding of OCCC pathophysiology, current therapeutic strategies, including ICIs and anti-angiogenic agents, have shown limited clinical efficacy in this cancer type. Nevertheless, emerging evidence from ongoing clinical trials suggests potential benefits from combinatorial therapies targeting multiple pathways. For instance, the combination of pembrolizumab with lenvatinib or VEGF inhibitors has demonstrated promising activity in subsets of OCCC patients, underscoring the importance of multi-targeted approaches. Similarly, preclinical studies suggest that inhibiting key molecules such as IL-6, HIF-1α, HDAC6, or IL-10, in combination with ICIs, could overcome resistance mechanisms and enhance treatment efficacy. Future therapeutic strategies should focus on leveraging the intricate interplay between the genetic and immunological features of OCCC. Targeting ARID1A-mutated tumors through specific inhibitors of HDAC6 or IL-6 signaling could reprogram the immunosuppressive TME and restore T-cell-mediated cytotoxicity. Additionally, continued exploration of innovative combinations, such as dual ICB (e.g., PD-1 and LAG-3 inhibition) may further expand the therapeutic armamentarium for this malignancy.
In conclusion, while OCCC remains a formidable clinical challenge, advances in molecular and immunologic research offer hope for more effective and durable therapeutic options. Future studies should prioritize the integration of targeted therapies with immunomodulatory agents to address the multifaceted nature of OCCC, ultimately improving outcomes for patients with this rare and aggressive cancer.
The authors acknowledge Lara Vecchi, Valentina Attanasio, and Aashni Shah (Polistudium Srl, Milan, Italy) for medical writing, editorial assistance, and English editing, and Massimiliano Pianta (Polistudium Srl, Milan, Italy) for graphic support.
Conflict of interest
SP received honoraria from MSD, Roche, GSK, Novartis, and PharmaMar; research funding from MSD, AZ, Pfizer, and GSK. CP received honoraria from MSD, AZ, GSK, and EISAI. MD received honoraria from MSD, IPSEN, and BMS. SR received honoraria from MSD, AZ, J&J, Astellas, Ipsen, Recordati, Accord, Novartis, and Pfizer.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesSiegelRLMillerKDJemalA.
Cancer statistics, 2019. CA Cancer J Clin. (2019) 69:7–34. doi: 10.3322/caac.21551, PMID: 30620402PratJD'AngeloEEspinosaI.
Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. (2018) 80:11–27. doi: 10.1016/j.humpath.2018.06.018, PMID: 29944973RodriguesSBragaMFélixACunhaTM.
Clear cell carcinoma of the ovary: Clues for radiologists to perform a correct diagnosis. Curr Probl Diagn Radiol. (2024) 53:271–9. doi: 10.1067/j.cpradiol.2023.10.003, PMID: 37925237SudaKCruz DiazLAYoshiharaKNakaokaHYachidaNMotoyamaT.
Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci. (2020) 111:3000–9. doi: 10.1111/cas.14507, PMID: 32473611SaavalainenLLassusHButATiitinenAHärkkiPGisslerM.
Risk of gynecologic cancer according to the type of endometriosis. Obstet Gynecol. (2018) 131:1095–102. doi: 10.1097/AOG.0000000000002624, PMID: 29742675PearceCLTemplemanCRossingMALeeANearAMWebbPM.
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. (2012) 13:385–94. doi: 10.1016/S1470-2045(11)70404-1, PMID: 22361336WorleyMJWelchWRBerkowitzRSNgSW.
Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. (2013) 14:5367–79. doi: 10.3390/ijms14035367, PMID: 23466883World Health Organization.
Tumours of the ovary and peritoneum. In:
TavassoliFADevileeP, editors. Pathology and genetics: Tumours of the breast and female genital organs, 3rd ed.
IARC Press, Lyon (France (2003). p. 113–216.
LongacreTAWellsMBellDAMalpicaAPratJRonnettBM.
Tumours of the ovary. In:
KurmanRJCarcangiuMLHerringtonSYoungRH, editors. WHO classification of tumours of female reproductive organs, 4th ed.
IARC Press, Lyon (2014). p. 11–86.
WinterWE3rdMaxwellGLTianCCarlsonJWOzolsRFRosePG.
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. (2007) 25:3621–7. doi: 10.1200/JCO.2006.10.2517, PMID: 17704411LiuZJingCKongF.
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer. J Ovarian Res. (2024) 17:39. doi: 10.1186/s13048-024-01359-7, PMID: 38347608AnglesioMSCareyMSKöbelMMackayHHuntsmanDG.
Vancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. (2011) 121:407–15. doi: 10.1016/j.ygyno.2011.01.005, PMID: 21276610JinYLiYPanL.
The target therapy of ovarian clear cell carcinoma. Onco Targets Ther. (2014) 7:1647–52. doi: 10.2147/OTT.S49993, PMID: 25285014DuskaLRGarrettLHenrettaMFerrissJSLeeLHorowitzN.
When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. (2010) 116:374–7. doi: 10.1016/j.ygyno.2009.10.069, PMID: 19922988MatsuoKHasegawaKYoshinoKMurakamiRHisamatsuTStoneRL.
Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer. (2015) 51:1978–88. doi: 10.1016/j.ejca.2015.07.012, PMID: 26238017DiazESWaltsAEKarlanBYWalshCS.
Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. (2013) 131:541–5. doi: 10.1016/j.ygyno.2013.09.005, PMID: 24041880MatsuuraYRobertsonGMarsdenDEKimSNGebskiVHackerNF.
Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol. (2007) 104:406–10. doi: 10.1016/j.ygyno.2006.08.026, PMID: 17014897ChanJKTeohDHuJMShinJYOsannKKappDS.
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. (2008) 109:370–6. doi: 10.1016/j.ygyno.2008.02.006, PMID: 18395777ItamochiHKigawaJTerakawaN.
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. (2008) 99:653–8. doi: 10.1111/j.1349-7006.2008.00747.x, PMID: 18377417MarksEIBrownVSDizonDS.
Genomic and molecular abnormalities in gynecologic clear cell carcinoma. Am J Clin Oncol. (2020) 43:139–45. doi: 10.1097/COC.0000000000000641, PMID: 31764020TangHLiuYWangXGuanLChenWJiangH.
Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort. Med (Baltimore). (2018) 97:e10881. doi: 10.1097/MD.0000000000010881, PMID: 29794794LeeHYHongJHByunJHKimHJBaekSKKimJY.
Clinical characteristics of clear cell ovarian cancer: a retrospective multicenter experience of 308 patients in South Korea. Cancer Res Treat. (2020) 52:277–83. doi: 10.4143/crt.2019.292, PMID: 31319640TanDSKayeS.
Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol. (2007) 60:355–60. doi: 10.1136/jcp.2006.040030, PMID: 17018684IidaYOkamotoAHollisRLGourleyCHerringtonCS.
Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. (2021) 31:605–16. doi: 10.1136/ijgc-2020-001656, PMID: 32948640YangQZhangCRenYYiHLuoTXingF.
Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing. Neoplasia. (2020) 22:399–430. doi: 10.1016/j.neo.2020.06.002, PMID: 32650224EnomotoTAokiDHattoriKJinushiMKigawaJTakeshimaN.
The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer. (2019) 29:1043–9. doi: 10.1136/ijgc-2019-000384, PMID: 31263023KobayashiTNishikimiKMitsuhashiAPiaoHMatsuokaAOtsukaS.
Suppressor-type TERT mutations associated with recurrence in ovarian clear cell carcinoma. Genes Chromosomes Cancer. (2023) 62:471–6. doi: 10.1002/gcc.23129, PMID: 36710084LeeSGarnerEIWelchWRBerkowitzRSMokSC.
Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol. (2007) 106:311–7. doi: 10.1016/j.ygyno.2007.03.041, PMID: 17532031StadlmannSGuethUBaumhoerDMochHTerraccianoLSingerG.
Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol. (2007) 26:341–4. doi: 10.1097/pgp.0b013e31802d692c, PMID: 17581422KatoNSasouSMotoyamaT.
Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. (2006) 19:83–9. doi: 10.1038/modpathol.3800492, PMID: 16258507SekiTYanaiharaNShapiroJSSaitoMTabataJYokomizoR.
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma. Sci Rep. (2021) 11:7689. doi: 10.1038/s41598-021-86913-9, PMID: 33833265YamashitaYAkatsukaSShinjoKYatabeYKobayashiHSekoH.
Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. PloS One. (2013) 8:e57724. doi: 10.1371/journal.pone.0057724, PMID: 23469222MabuchiSSugiyamaTKimuraT.
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol. (2016) 27:e31. doi: 10.3802/jgo.2016.27.e31, PMID: 27029752KöbelMPiskorzAMLeeSLuiSLePageCMarassF.
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. (2016) 2:247–58. doi: 10.1002/cjp2.53, PMID: 27840695YoshidaKYoshikawaNShirakawaANiimiKSuzukiSKajiyamaH.
Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. J Gynecol Oncol. (2019) 30:e85. doi: 10.3802/jgo.2019.30.e85, PMID: 31576683ChandlerRLDamrauerJSRaabJRSchislerJCWilkersonMDDidionJP.
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun. (2015) 6:6118. doi: 10.1038/ncomms7118, PMID: 25625625LiJWangWZhangYCieślikMGuoJTanM.
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. (2020) 130:2712–26. doi: 10.1172/JCI134402, PMID: 32027624YanoMKatohTMiyazawaMOganeNMiwaMHasegawaK.
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. Sci Rep. (2019) 9:2397. doi: 10.1038/s41598-019-38653-0, PMID: 30787326PhamTQRobinsonKXuLPavlovaMNSkapekSXChenEY.
HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma. Oncogene. (2021) 40:578–91. doi: 10.1038/s41388-020-01550-2, PMID: 33199827HsiehTHHsuCYWuCWWangSHYehCHChengKH.
Vorinostat decrease M2 macrophage polarization through ARID1A6488delG/HDAC6/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma. BioMed Pharmacother. (2023) 161:114500. doi: 10.1016/j.biopha.2023.114500, PMID: 36958195YamamotoSTsudaHTakanoMTamaiSMatsubaraO.
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. (2012) 25:615–24. doi: 10.1038/modpathol.2011.189, PMID: 22157930MadsenRRVanhaesebroeckBSempleRK.
Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. (2018) 24:856–70. doi: 10.1016/j.molmed.2018.08.003, PMID: 30197175YagyuTTsujiYHarutaSKitanakaTYamadaYKawaguchiR.
Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int J Gynecol Cancer. (2006) 16:1545–51. doi: 10.1111/j.1525-1438.2006.00625.x, PMID: 16884363KuoKTMaoTLJonesSVerasEAyhanAWangTL.
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. (2009) 174:1597–601. doi: 10.2353/ajpath.2009.081000, PMID: 19349352Perez-JuarezCEArechavaleta-VelascoFZeferino-ToqueroMAlvarez-ArellanoLEstrada-MoscosoIDiaz-CuetoL.
Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors. Med Oncol. (2019) 37:4. doi: 10.1007/s12032-019-1326-5, PMID: 31713081IidaYAokiKAsakuraTUedaKYanaiharaNTakakuraS.
Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol. (2012) 40:2122–30. doi: 10.3892/ijo.2012.1406, PMID: 22447231WangSLuJYouQHuangHChenYLiuK.
The mTOR/AP-1/VEGF signaling pathway regulates vascular endothelial cell growth. Oncotarget. (2016) 7:53269–76. doi: 10.18632/oncotarget.10756, PMID: 27458160SuHPengCLiuY.
Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer. Front Cell Dev Biol. (2024) 12:1372330. doi: 10.3389/fcell.2024.1372330, PMID: 38562143FurutakeYYamaguchiKYamanoiKKitamuraSTakamatsuSTakiM.
YAP1 suppression by ZDHHC7 is associated with ferroptosis resistance and poor prognosis in ovarian clear cell carcinoma. Mol Cancer Ther. (2024) 23:1652–65. doi: 10.1158/1535-7163.MCT-24-0145, PMID: 38958503XuWYangZXieCZhuYShuXZhangZ.
PTEN lipid phosphatase inactivation links the Hippo and PI3K/Akt pathways to induce gastric tumorigenesis. J Exp Clin Cancer Res. (2018) 37:198. doi: 10.1186/s13046-018-0795-2, PMID: 30134988ChenJJiangCCJinLZhangXD.
Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. (2016) 27:409–16. doi: 10.1093/annonc/mdv615, PMID: 26681673ShenJJuZZhaoWWangLPengYGeZ.
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. (2018) 24:556–62. doi: 10.1038/s41591-018-0012-z, PMID: 29736026ChangQDalyLBrombergJ.
The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol. (2014) 26:48–53. doi: 10.1016/j.smim.2014.01.007, PMID: 24613573YanaiharaNHirataYYamaguchiNNoguchiYSaitoMNagataC.
Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog. (2016) 55:832–41. doi: 10.1002/mc.22325, PMID: 25856562KawabataAYanaiharaNNagataCSaitoMNoguchiDTakenakaM.
Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. Gynecol Oncol. (2017) 146:609–14. doi: 10.1016/j.ygyno.2017.06.027, PMID: 28673661MehnerCMillerEHocklaACobanMWerohaSJRadiskyDC.
Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. Oncogene. (2020) 39:6606–18. doi: 10.1038/s41388-020-01451-4, PMID: 32929152XuSYuCMaXLiYShenYChenY.
IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells. Eur J Pharmacol. (2021) 894:173817. doi: 10.1016/j.ejphar.2020.173817, PMID: 33345849YanaiharaNAnglesioMSOchiaiKHirataYSaitoMNagataC.
Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol. (2012) 41:1094–100. doi: 10.3892/ijo.2012.1533, PMID: 22751940MabuchiSKawaseCAltomareDAMorishigeKHayashiMSawadaK.
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. (2010) 9:2411–22. doi: 10.1158/1535-7163.MCT-10-0169, PMID: 20663925BourhisMPalleJGaly-FaurouxITermeM.
Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. Front Immunol. (2021) 12:616837. doi: 10.3389/fimmu.2021.616837, PMID: 33854498AmanoYMandaiMYamaguchiKMatsumuraNKharmaBBabaT.
Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival. Oncotarget. (2015) 6:26002–17. doi: 10.18632/oncotarget.4692, PMID: 26318292MatsuzakiSYoshinoKUedaYMatsuzakiSKakudaMOkazawaA.
Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives. Cancer Cell Int. (2015) 15:117. doi: 10.1186/s12935-015-0267-0, PMID: 26675567HervieuAKermorgantS.
The role of PI3K in Met driven cancer: a recap. Front Mol Biosci. (2018) 5:86. doi: 10.3389/fmolb.2018.00086, PMID: 30406111FurgeKAKiewlichDLePVoMNFaureMHowlettAR.
Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA. (2001) 98:10722–7. doi: 10.1073/pnas.191067898, PMID: 11535809SmythECSclafaniFCunninghamD.
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther. (2014) 7:1001–14. doi: 10.2147/OTT.S44941, PMID: 24959087ZhaoPLiLJiangXLiQ.
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. (2019) 12:54. doi: 10.1186/s13045-019-0738-1, PMID: 31151482NojadehJNBehrouz SharifSSakhiniaE.
Microsatellite instability in colorectal cancer. EXCLI J. (2018) 17:159–68. doi: 10.17179/excli2017-948, PMID: 29743854PalTAkbariMRSunPLeeJHFulpJThompsonZ.
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer. (2012) 107:1783–90. doi: 10.1038/bjc.2012.452, PMID: 23047549DuránMFaullILastraELaesJFRodrigoABSánchez-EscribanoR.
ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report. J Med Case Rep. (2021) 15:89. doi: 10.1186/s13256-020-02589-1, PMID: 33608032GeHXiaoYQinGGuYCaiXJiangW.
Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma. Diagn Pathol. (2021) 16:12. doi: 10.1186/s13000-021-01071-w, PMID: 33541386HowittBEStricklandKCShollLMRodigSRitterhouseLLChowdhuryD.
Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. (2017) 6:e1277308. doi: 10.1080/2162402X.2016.1277308, PMID: 28344892BennettJAMorales-OyarvideVCampbellSLongacreTAOlivaE.
Mismatch repair protein expression in clear cell carcinoma of the ovary: incidence and morphologic associations in 109 cases. Am J Surg Pathol. (2016) 40:656–63. doi: 10.1097/PAS.0000000000000602, PMID: 26813747LinSYHangJFLinYYLaiCRHoHLChouTY.
Diffuse intratumoral stromal inflammation in ovarian clear cell carcinoma is associated with loss of mismatch repair protein and high PD-L1 expression. Int J Gynecol Pathol. (2021) 40:148–55. doi: 10.1097/PGP.0000000000000682, PMID: 32897958LeDTDurhamJNSmithKNWangHBartlettBRAulakhLK.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. (2017) 357:409–13. doi: 10.1126/science.aan6733, PMID: 28596308ZhaoQJiangYXiangSKaboliPJShenJZhaoY.
Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front Immunol. (2021) 30:658753. doi: 10.3389/fimmu.2021.658753, PMID: 33859650JinJWuXYinJLiMShenJLiJ.
Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy. Front Oncol. (2019) 9:263. doi: 10.3389/fonc.2019.00263, PMID: 31058077XiangSLiJShenJZhaoYWuXLiM.
e identification of prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Front Immunol. (2021) 12:653836. doi: 10.3389/fimmu.2021.653836, PMID: 33897701TawbiHASChadendorfDLipsonEJAsciertoPAMatamalaLCastillo GutiérrezE.
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. (2022) 386:24–34. doi: 10.1056/NEJMoa2109970, PMID: 34986285ErdoganBWebbDJ.
Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. (2017) 45:229–36. doi: 10.1042/BST20160387, PMID: 28202677RiceAJCortesELachowskiDCheungBCHKarimSAMortonJP.
Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis. (2017) 6:e352. doi: 10.1038/oncsis.2017.54, PMID: 28671675Peña-RomeroACOrenes-PiñeroE.
Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers. Cancers (Basel). (2022) 14:1681. doi: 10.3390/cancers14071681, PMID: 35406451MaibachFSadozaiHSeyed JafariSMHungerRESchenkM.
Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. (2020) 11:2105. doi: 10.3389/fimmu.2020.02105, PMID: 33013886ChenDSMellmanI.
Oncology meets immunology: the cancer-immunity cycle. Immunity. (2013) 39:1–10. doi: 10.1016/j.immuni.2013.07.012, PMID: 23890059GuoQHuangFGoncalvesCDel RincónSVMillerWHJr.
Translation of cancer immunotherapy from the bench to the bedside. Adv Cancer Res. (2019) 143:1–62. doi: 10.1016/bs.acr.2019.03.001, PMID: 31202357WoanKVMillerJS.
Harnessing natural killer cell antitumor immunity: from the bench to bedside. Cancer Immunol Res. (2019) 7:1742–7. doi: 10.1158/2326-6066.CIR-19-0404, PMID: 31676567AndersonNRMinutoloNGGillSKlichinskyM.
Macrophage-based approaches for cancer immunotherapy. Cancer Res. (2021) 81:1201–8. doi: 10.1158/0008-5472.CAN-20-2990, PMID: 33203697WuHLiPShaoNMaJJiMSunX.
Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncol Lett. (2012) 3:1119–23. doi: 10.3892/ol.2012.614, PMID: 22783403SahaiEAstsaturovICukiermanEDeNardoDGEgebladMEvansRM.
A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. (2020) 20:174–86. doi: 10.1038/s41568-019-0238-1, PMID: 31980749BaghbanRRoshangarLJahanban-EsfahlanRSeidiKEbrahimi-KalanAJaymandM.
Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. (2020) 18:59. doi: 10.1186/s12964-020-0530-4, PMID: 32264958QinSXuLYiMYuSWuKLuoS.
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. (2019) 18:155. doi: 10.1186/s12943-019-1091-2, PMID: 31690319BuchbinderEIDesaiA.
CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. (2016) 39:98–106. doi: 10.1097/COC.0000000000000239, PMID: 26558876WooSRTurnisMEGoldbergMVBankotiJSelbyMNirschlCJ.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. (2012) 72:917–27. doi: 10.1158/0008-5472.CAN-11-1620, PMID: 22186141HarrisAL.
Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. (2002) 2:38–47. doi: 10.1038/nrc704, PMID: 11902584ChaturvediPGilkesDMTakanoNSemenzaGL.
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci USA. (2014) 111:E2120–9. doi: 10.1073/pnas.1406655111, PMID: 24799675FridlenderZGAlbeldaSM.
Tumor-associated neutrophils: friend or foe? Carcinogenesis. (2012) 33:949–55. doi: 10.1093/carcin/bgs123, PMID: 22425643KalluriR.
The biology and function of fibroblasts in cancer. Nat Rev Cancer. (2016) 16:582–98. doi: 10.1038/nrc.2016.73, PMID: 27550820BeattyGLGladneyWL.
Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. (2015) 21:687–92. doi: 10.1158/1078-0432.CCR-14-1860, PMID: 25501578PolyakKHavivICampbellIG.
Co-evolution of tumor cells and their microenvironment. Trends Genet. (2009) 25:30–8. doi: 10.1016/j.tig.2008.10.012, PMID: 19054589YangYYangYYangJZhaoXWeiX.
Tumor microenvironment in ovarian cancer: function and therapeutic strategy. Front Cell Dev Biol. (2020) 8:758. doi: 10.3389/fcell.2020.00758, PMID: 32850861MoriYOkimotoYSakaiHKandaYOhataHShiokawaD.
Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer. Cell Rep Med. (2024) 5:101532. doi: 10.1016/j.xcrm.2024.101532, PMID: 38670097AtiyaHIFrisbieLGoldfeldEOrellanaTDonnellanNModugnoF.
Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation. Cancer Res. (2022) 82:4680–93. doi: 10.1158/0008-5472.CAN-22-1294, PMID: 36219681OdaKHamanishiJMatsuoKHasegawaK.
Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management. Gynecol Oncol. (2018) 151:381–9. doi: 10.1016/j.ygyno.2018.09.001, PMID: 30217369HamanishiJMandaiMIkedaTMinamiMKawaguchiAMurayamaT.
Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. (2015) 33:4015–22. doi: 10.1200/JCO.2015.62.3397, PMID: 26351349WillisBCSloanEAAtkinsKAStolerMHMillsAM.
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol. (2017) 30:1622–32. doi: 10.1038/modpathol.2017.67, PMID: 28752845ChengBLiangHJiangTChenJWangG.
Characterization of PD-L1 expression and its prognostic value in patients with ovarian cancer. Transl Cancer Res. (2018) 7:1271–81. doi: 10.21037/tcr.2018.10.11DevlinMJMillerRLaforetsFKotantakiPGarsedDWKristeleitR.
The tumor microenvironment of clear-cell ovarian cancer. Cancer Immunol Res. (2022) 10:1326–39. doi: 10.1158/2326-6066.CIR-22-0407, PMID: 36095166CassarEKartikasariAERPlebanskiM.
Regulatory T cells in ovarian carcinogenesis and future therapeutic opportunities. Cancers (Basel). (2022) 14:5488. doi: 10.3390/cancers14225488, PMID: 36428581KimEHSullivanJAPlischEHTejeraMMJatzekAChoiKY.
Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol. (2012) 188:4305–14. doi: 10.4049/jimmunol.1103568, PMID: 22467649HemonPJean-LouisFRamgolamKBrignoneCViguierMBachelezH.
MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. (2011) 186:5173–83. doi: 10.4049/jimmunol.1002050, PMID: 21441454EfimovaOVKelleyTW.
Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway. BMC Immunol. (2009) 10:59. doi: 10.1186/1471-2172-10-59, PMID: 19930596LastwikaKJWilsonW3rdLiQKNorrisJXuHGhazarianSR.
Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. (2016) 76:227–38. doi: 10.1158/0008-5472.CAN-14-3362, PMID: 26637667ZaitsuSYanoMAdachiSMiwaMKatohTKawanoY.
Lymphocyte-activation gene 3 protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma. J Ovarian Res. (2023) 16:93. doi: 10.1186/s13048-023-01179-1, PMID: 37179337BitlerBGWuSParkPHHaiYAirdKMWangY.
ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol. (2017) 19:962–73. doi: 10.1038/ncb3582, PMID: 28737768GoodeELBlockMSKalliKRVierkantRAChenWFogartyZC.
Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. (2017) 3:e173290. doi: 10.1001/jamaoncol.2017.3290, PMID: 29049607KimSRCloutierBTLeungSCochraneDBrittonHPinaA.
Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification. Gynecol Oncol. (2020) 158:3–11. doi: 10.1016/j.ygyno.2020.04.043, PMID: 32331700ZhanJZhangMZhouLHeC.
Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy. Front Bioeng Biotechnol. (2023) 11:1065773. doi: 10.3389/fbioe.2023.1065773, PMID: 36994358MooreKNBookmanMSehouliJMillerAAndersonCScambiaG.
Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. (2021) 39:1842–55. doi: 10.1200/JCO.21.00306, PMID: 33891472HamanishiJTakeshimaNKatsumataNUshijimaKKimuraTTakeuchiS.
Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. (2021) 39:3671–81. doi: 10.1200/JCO.21.00334, PMID: 34473544MatulonisUAShapira-FrommerRSantinADLisyanskayaASPignataSVergoteI.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. (2019) 30:1080–7. doi: 10.1093/annonc/mdz135, PMID: 31046082ZamarinDBurgerRASillMWPowellDJJrLankesHAFeldmanMD.
Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology study. J Clin Oncol. (2020) 38:1814–23. doi: 10.1200/JCO.19.02059, PMID: 32275468DizonDSMathewsCADavidSMMachanJTHadfieldMJMarksEI.
Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. J Clin Oncol. (2024) 42:LBA5500. doi: 10.1200/JCO.2024.42.17_suppl.LBA5500MakkerVColomboNCasado HerráezASantinADColombaEMillerDS.
Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. (2022) 386:437–48. doi: 10.1056/NEJMoa2108330, PMID: 35045221MarthCTarnawskiRTyulyandinaAPignataSGilbertLKaenD.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. (2022) 32:93–100. doi: 10.1136/ijgc-2021-003017, PMID: 34799418KimBGChoiCHNgoiNTanDKimJWKimJW.
Preliminary efficacy of pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: phase II LARA trial (GCGS-OV4/APGOT-OV3). Presented at: 39th Annu Meeting Korean Soc Gynecologic Oncol. (2024). doi: 10.3802/jgo.2024.35.S2.P21Pembrolizumab and lenvatinib in clear cell ovarian cancer . Available online at: https://clinicaltrials.gov/study/NCT05296512.
González-MartínAChungHCSaada-BouzidEYanezESenellartHCassierPA.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. (2024) 186:182–90. doi: 10.1016/j.ygyno.2024.04.011, PMID: 38718741McNamaraBBelloneSDemirkiranCHartwichTMPSantinAD.
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy. Gynecol Oncol Rep. (2023) 48:101218. doi: 10.1016/j.gore.2023.101218, PMID: 37325296A study of pembrolizumab in patients with advanced gynaecological clear cell cancer (PEACOCC) . Available online at: https://clinicaltrials.gov/study/NCT03425565.
Sintilimab plus bevacizumab in recurrent/persistent ovarian clear cell carcinoma (INOVA). Available online at: https://clinicaltrials.gov/study/NCT04735861.
LiuXXiaBZhangWSunLFengCHuangY.
522MO Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): a multicenter, single-arm, phase II trial. Ann Oncol. (2022) 33:S235–82. doi: 10.1016/annonc/annonc1054Study on pembrolizumab in recurrent, platinum resistant, CPS >1 positive ovarian, fallopian tube and primary peritoneal cancer patients (MITO 27) . Available online at: https://www.clinicaltrials.gov/study/NCT04375956.
TanDSPChoiCHNgoiNSunHHeongVOwSGW.
A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3). J Clin Oncol. (2022) 40:5565. doi: 10.1200/JCO.2022.40.16_suppl.5565A study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors (BOUQUET) . Available online at: https://clinicaltrials.gov/study/NCT04931342.
Ray-CoquardILPignataSLeeJYColemanRLBrownJKimJW.
747MO First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: cobimetinib or atezolizumab + bevacizumab for persistent/recurrent rare epithelial ovarian cancer. Ann Oncol. (2023) 34:S511–2. doi: 10.1016/j.annonc.2023.09.1926BrUOG 354 nivolumab +/- ipilimumab for ovarian and extra-renal clear cell carcinomas . Available online at: https://clinicaltrials.gov/study/NCT03355976.
Trial of lenvatinib plus pembrolizumab in recurrent gynecological clear cell adenocarcinomas (LARA) . Available online at: https://clinicaltrials.gov/study/NCT04699071.
EON: A single-arm phase II study of etigilimab (OMP-313M32) in combination with checkpoint inhibition (Nivolumab) in patients with platinum-resistant, recurrent epithelial ovarian cancer . Available online at: https://clinicaltrials.gov/study/NCT05026606.
A study of xmAb20717 (Vudalimab)in patients with selected advanced gynecologic and genitourinary Malignancies . Available online at: https://clinicaltrials.gov/study/NCT05032040.
FukumotoTFatkhutdinovNZundellJATcyganovENNacarelliTKarakashevS.
HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Res. (2019) 79:5482–9. doi: 10.1158/0008-5472.CAN-19-1302, PMID: 31311810JeongWParkSRRapisardaAFerNKindersRJChenA.
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. Invest New Drugs. (2014) 32:340–6. doi: 10.1007/s10637-013-0048-3, PMID: 24242862NorrisREShustermanSGoreLMuscalJAMacyMEFoxE.
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children, adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. (2014) 61:1792–7. doi: 10.1002/pbc.25105, PMID: 24962521LuoFLuFTCaoJXMaWJXiaZFZhanJH.
HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer. Cancer Lett. (2022) 531:39–56. doi: 10.1016/j.canlet.2022.01.027, PMID: 35090965LinYCWenKCSungPLChouYTLiewPLChenLY.
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. J Ovarian Res. (2020) 13:143. doi: 10.1186/s13048-020-00751-3, PMID: 33292376BentEHMillan-BareaLRZhuangIGouletDRFroseJHemannMT.
Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nat Commun. (2021) 12:6218. doi: 10.1038/s41467-021-26407-4, PMID: 34711820SilvaJRSalesNSSilvaMOApsLRMMMorenoACRRodriguesEG.
Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model. Cancer Immunol Immunother. (2019) 68:753–63. doi: 10.1007/s00262-018-02297-2, PMID: 30806747NiGWangYCumminsSWaltonSMounseyKLiuX.
Inhibitory mechanism of peptides with a repeating hydrophobic and hydrophilic residue pattern on interleukin-10. Hum Vaccin Immunother. (2017) 13:518–27. doi: 10.1080/21645515.2016.1238537, PMID: 27686406BerezhnoyAStewartCAMcNamaraJO2ndThielWGiangrandePTrinchieriG.
Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. Mol Ther. (2012) 20:1242–50. doi: 10.1038/mt.2012.18, PMID: 22434135Alpelisib .
FDA. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf.
PassarelliACarboneVPignataSMazzeoRLorussoDScambiaG.
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity. Gynecol Oncol. (2024) 183:61–7. doi: 10.1016/j.ygyno.2024.02.029, PMID: 38518529PassarelliAVentrigliaJPisanoCCecereSCNapoliMDRossettiS.
The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer. Front Oncol. (2023) 12:1088962. doi: 10.3389/fonc.2022.1088962, PMID: 36713525
Edited by: Nicole James, Women & Infants Hospital of Rhode Island, United States
Reviewed by: Sajad A Dar, Jazan University, Saudi Arabia
Anna Pawłowska-Łachut, Medical University of Lublin, Poland